Literature DB >> 11027663

Flt3 ligand induces tyrosine phosphorylation of gab1 and gab2 and their association with shp-2, grb2, and PI3 kinase.

S Zhang1, H E Broxmeyer.   

Abstract

The receptor tyrosine kinase Flt3 has been shown to play an important role in proliferation, differentiation, and survival of hematopoietic stem and progenitor cells. Although some postreceptor signaling events of Flt3 have been characterized, the involvement of Gab family proteins in Flt3 signaling is not known. In this study, we show that both Gab1 and Gab2 are rapidly tyrosine phosphorylated after Flt3 ligand stimulation of Flt3 ligand-responsive cells. They interact with tyrosine-phosphorylated Shp-2, p85, Grb2, and Shc. The results suggest that Gab proteins are engaged in Flt3 signaling to mediate downstream activation of Shp-2 and PI3 kinase pathways and possibly the Ras/Raf/MAPK pathway. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11027663     DOI: 10.1006/bbrc.2000.3662

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  33 in total

1.  Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.

Authors:  Jennifer L Rocnik; Rachel Okabe; Jin-Chen Yu; Benjamin H Lee; Neill Giese; David P Schenkein; D Gary Gilliland
Journal:  Blood       Date:  2006-04-20       Impact factor: 22.113

Review 2.  A STATus report on DC development.

Authors:  Haiyan S Li; Stephanie S Watowich
Journal:  J Leukoc Biol       Date:  2012-05-01       Impact factor: 4.962

3.  Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT.

Authors:  Raghuveer Singh Mali; Peilin Ma; Li-Fan Zeng; Holly Martin; Baskar Ramdas; Yantao He; Emily Sims; Sarah Nabinger; Joydeep Ghosh; Namit Sharma; Veerendra Munugalavadla; Anindya Chatterjee; Shuo Li; George Sandusky; Andrew W Craig; Kevin D Bunting; Gen-Sheng Feng; Rebecca J Chan; Zhong-Yin Zhang; Reuben Kapur
Journal:  Blood       Date:  2012-07-17       Impact factor: 22.113

4.  A critical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells.

Authors:  Liang Li; Hardik Modi; Tinisha McDonald; John Rossi; Jiing-Kuan Yee; Ravi Bhatia
Journal:  Blood       Date:  2011-06-13       Impact factor: 22.113

Review 5.  Innate immune regulation by STAT-mediated transcriptional mechanisms.

Authors:  Haiyan S Li; Stephanie S Watowich
Journal:  Immunol Rev       Date:  2014-09       Impact factor: 12.988

6.  Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.

Authors:  Obdulio Piloto; Melissa Wright; Patrick Brown; Kyu-Tae Kim; Mark Levis; Donald Small
Journal:  Blood       Date:  2006-10-17       Impact factor: 22.113

Review 7.  Excessive Reactive Oxygen Species and Exotic DNA Lesions as an Exploitable Liability.

Authors:  Safnas F AbdulSalam; Fathima Shazna Thowfeik; Edward J Merino
Journal:  Biochemistry       Date:  2016-09-13       Impact factor: 3.162

8.  Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease.

Authors:  Katharine A Whartenby; Peter A Calabresi; Erin McCadden; Bao Nguyen; David Kardian; Tianhong Wang; Claudio Mosse; Drew M Pardoll; Donald Small
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-04       Impact factor: 11.205

Review 9.  Signal transduction of oncogenic Flt3.

Authors:  Chunaram Choudhary; Carsten Müller-Tidow; Wolfgang E Berdel; Hubert Serve
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

10.  Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).

Authors:  David B Rosen; Mark D Minden; Steven M Kornblau; Aileen Cohen; Urte Gayko; Santosh Putta; John Woronicz; Erik Evensen; Wendy J Fantl; Alessandra Cesano
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.